Dr Paul Barr speaks to ecancer at the 2019 ASH meeting about the safety and efficacy of umbralisib ublituximab and venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL).
He explains the premise of this phase I/II study, which seeks to evaluate this therapeutic combination which aims to achieve deeper remissions with the shortest amount of therapy in these patients.
He describes the results of this trial, in which this drug combination had a manageable safety profile, with no evidence of tumour lysis syndrome at the recommended phase II dose of 800 milligrams.
Future phases will need to assess the longer term outcomes, including progression-free survival, but Dr Barr believes these results show promising tolerability and efficacy.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.